Navigation Links
'EuroVacc 02' HIV Vaccine Trial Begins

different "antigen transporters" (vectors). A first dose of antigen A in vector X is administered, followed by a booster using the same antigen A in vector Y this time. In this way, immune reactions to, and the consequent inhibition of the transporter are reduced. The first injections prime the immune system whereas the second injections further enhance (boost) the immune response. Therefore this combined vaccine strategy is expected to strengthen stimulation of the immune response

While there is a need to identify the best candidates for the "prime" and the most efficient for the "boost", results from recent pre-clinical studies in non-human primates conducted by EuroVacc suggest that the use of the DNA as prime followed by a boost based on poxvirus (NYVAC in this trial) induces stronger immune responses than either vaccine alone.


'"/>

Source:Imperial College London


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EuroVacc HIV Vaccine Trial Begins

(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... lichens can break down the infectious proteins responsible for chronic ... deer and elk and spreading throughout the United States and ... the journal PLoS ONE . Like other ... prions. One of the best-known of these diseases is "mad ...
... conducted at the University of Pennsylvania School of ... theoretical question: Will microorganisms swim faster or slower ... swimming, undulation, the answer is "slower." Paulo ... mechanics, along with student Xiaoning Shen, conducted the ...
... Carolina State University shows that a "gatekeeper" protein plays an ... The protein, C/EBP alpha, is normally abundantly expressed to ... exposed to sunlight. The NC State research shows, however, that ... are present. Moreover, when the protein is inactivated in ...
Cached Biology News:Lichens may aid in combating deadly chronic wasting disease in wildlife 2Penn research answers long-standing question about swimming in elastic liquids 2Lack of 'gatekeeper' protein linked to skin cancer 2
(Date:2/28/2015)... February 28, 2015 Increasing its efforts to ... launches its first three episodes of The GMO TRUTH podcast ... this month, as it continues its mission to discover the ... project's first phase, to “uncover the truth about the GMOs ... , The GMO Truth Podcast is an expansion of the ...
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... its newly developed Bruton,s tyrosine kinase (BTK) inhibitor ... The results of these preclinical evaluations have been ... The feedback received from the Agency is supportive ... Additional preclinical work is required to begin a ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... July 21 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... Wednesday, July 28, 2010 , after the market closes. The press release ... which will be open to the public via telephone and webcast. During the ... matters. , , , ...
... TRIANGLE PARK, N.C. , July 21 Chimerix, Inc., ... has expanded its clinical management team with the appointment of ... Herve Mommeja-Marin, MD, as Vice President of Clinical Research.   , ... In these new ...
... MA , July 21 /PRNewswire-FirstCall/ - SemBioSys Genetics ... proteins and oils utilizing its novel plant expression systems, today ... as President of US and International Operations. Mr. Pierce will ... will offer the Company a broader market to better exploit ...
Cached Biology Technology:Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents 2SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents 3SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents 4
... the macro- and micronutrients as ... (1962) and the vitamins as ... (1968). Preparation Quantity Equivalency: Formulated ... powder per liter of medium. ...
... Total Canine Endostatin. Canine Cytokine ... products include a line of enzyme-linked ... reagents used for multiple research applications. ... are ultra-sensitive, quick and dependable assays. ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... Biosystems and MDS Sciex present the ... high performance hybrid triple quadrupole/linear ion ... discovery, drug development or proteomics researcher. ... from the leaders in mass spectrometry ...
Biology Products: